Androgen deprivation therapy and side effects : Are GnRH antagonists safer?
(2021) In Asian Journal of Andrology 23(1). p.3-10- Abstract
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH), thereby lowering testosterone to castrate levels. This is associated with adverse events (AEs), including cardiovascular (CV) disorders, bone fractures, metabolic dysfunction, and impaired cognitive function. This literature review discusses these AEs, with a focus on CV and bone-related events. A hypothesis-generating meta-analysis of six clinical trials showed a potentially increased risk for CV disorders with GnRH agonists versus the GnRH antagonist degarelix. While no study has... (More)
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH), thereby lowering testosterone to castrate levels. This is associated with adverse events (AEs), including cardiovascular (CV) disorders, bone fractures, metabolic dysfunction, and impaired cognitive function. This literature review discusses these AEs, with a focus on CV and bone-related events. A hypothesis-generating meta-analysis of six clinical trials showed a potentially increased risk for CV disorders with GnRH agonists versus the GnRH antagonist degarelix. While no study has directly compared GnRH agonists versus antagonists with a primary CV outcome, one hypothesis for this observation is that GnRH agonists lead to initial surges in FSH that may negatively impact CV health, whereas antagonists do not. GnRH agonists are associated with metabolic and cognitive AEs and while data are lacking for GnRH antagonists, no differences in risk are predicted. Other common AEs with ADT include injection site reactions, which are much more common with degarelix than with GnRH agonists, which may reflect differing administration and injection techniques. Future studies are needed to further evaluate and compare the safety profiles of GnRH agonists and antagonists, especially in patients with pre-existing CV disease and other co-morbidities. Physicians should carefully evaluate benefits and risks when prescribing ADT and ensure that side effects are well managed.
(Less)
- author
- Freedland, Stephen and Abrahamsson, Per Anders LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- androgen antagonists, metabolic syndrome, prostate cancer, safety
- in
- Asian Journal of Andrology
- volume
- 23
- issue
- 1
- pages
- 8 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:32655041
- scopus:85099448679
- ISSN
- 1008-682X
- DOI
- 10.4103/aja.aja_22_20
- language
- English
- LU publication?
- yes
- id
- 80c88486-1c0c-4b1a-9a0a-f515b667d00c
- date added to LUP
- 2021-01-28 11:29:50
- date last changed
- 2024-11-14 23:18:41
@article{80c88486-1c0c-4b1a-9a0a-f515b667d00c,
abstract = {{<p>Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH), thereby lowering testosterone to castrate levels. This is associated with adverse events (AEs), including cardiovascular (CV) disorders, bone fractures, metabolic dysfunction, and impaired cognitive function. This literature review discusses these AEs, with a focus on CV and bone-related events. A hypothesis-generating meta-analysis of six clinical trials showed a potentially increased risk for CV disorders with GnRH agonists versus the GnRH antagonist degarelix. While no study has directly compared GnRH agonists versus antagonists with a primary CV outcome, one hypothesis for this observation is that GnRH agonists lead to initial surges in FSH that may negatively impact CV health, whereas antagonists do not. GnRH agonists are associated with metabolic and cognitive AEs and while data are lacking for GnRH antagonists, no differences in risk are predicted. Other common AEs with ADT include injection site reactions, which are much more common with degarelix than with GnRH agonists, which may reflect differing administration and injection techniques. Future studies are needed to further evaluate and compare the safety profiles of GnRH agonists and antagonists, especially in patients with pre-existing CV disease and other co-morbidities. Physicians should carefully evaluate benefits and risks when prescribing ADT and ensure that side effects are well managed.</p>}},
author = {{Freedland, Stephen and Abrahamsson, Per Anders}},
issn = {{1008-682X}},
keywords = {{androgen antagonists; metabolic syndrome; prostate cancer; safety}},
language = {{eng}},
number = {{1}},
pages = {{3--10}},
publisher = {{Nature Publishing Group}},
series = {{Asian Journal of Andrology}},
title = {{Androgen deprivation therapy and side effects : Are GnRH antagonists safer?}},
url = {{http://dx.doi.org/10.4103/aja.aja_22_20}},
doi = {{10.4103/aja.aja_22_20}},
volume = {{23}},
year = {{2021}},
}